Opendata, web and dolomites


ImmuNogenomics TArgeting Cancer

Total Cost €


EC-Contrib. €






 INTACt project word cloud

Explore the words cloud of the INTACt project. It provides you a very rough idea of what is the project "INTACt" about.

manner    rna    expended    serves    investments    treatment    unnecessary    candidates    unlike    returned    therapy    plasma    melanoma    biased    eliminated    genetic    models    creation    mediated    enormous    limitation    costly    strategies    lethal    immunotherapy    breakthroughs    emphasizes    consequence    lack    time    types    tool    significantly    antigen    designing    showing    cancer    cells    tumors    resistant    worldwide    recognition    innovative    caused    holds    therapeutic    patient    psychological    landscape    ultimate    poc    throughput    promise    neo    antigens    chemotherapy    drug    incidence    systematic    pressured    mutations    distinctive    composition    consuming    vaccines    lower    pharmaceutical    skin    combined    efficacy    arise    business    cell    intact    economic    immunological    xenografts    therapies    industry    person    lines    realizing    immune    tumor    genome    fresh    toxicities    reactive    burden    signature    patients    ones    designed    personalized    highlighted    mortality    commercializing    aggressive   

Project "INTACt" data sheet

The following table provides information about the project.


Organization address
address: HERZL STREET 234
postcode: 7610001

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2018-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) coordinator 150˙000.00


 Project objective

Melanoma is the most aggressive, treatment-resistant and lethal type of skin cancer. Its increasing incidence worldwide emphasizes the need for new treatment strategies. Major recent breakthroughs in melanoma therapy have highlighted the role of immune T cell-mediated responses against tumor cells, showing that immune-system recognition of neo-antigens on cancer cells serves as a distinctive immunological signature. However, current strategies to identify neo-antigens are biased, costly and time-consuming. Directly addressing this major therapeutic limitation, this PoC project is aimed at commercializing an innovative tool, called INTACt, for designing highly personalized therapies for melanoma patients, ones that efficiently target the composition of patient-specific neo-antigens that arise as a consequence of mutations in a patient’s melanoma genome. INTACt is designed to identify neo-antigens in a high-throughput, systematic and cost-effective manner in cell lines, fresh tumors, patient-derived xenografts and plasma. INTACt will further identify the patient neo-antigen-reactive T cells to then be returned to the patient, using neo-antigen-specific T cells or RNA vaccines. Such personalized targeting of the patient’s melanoma genetic landscape is key to a significantly improved mortality. Unlike existing therapeutic strategies, INTACt may be considered the ultimate personalized immune therapy for the treatment of melanoma patients to be expended to other cancer types. This patient-specific tool will significantly lower patients’ economic and psychological burden caused by unnecessary chemotherapy and targeted therapy. INTACt also holds the promise of realizing value from enormous past investments in drug candidates that were eliminated due to person-specific toxicities or lack of efficacy as these can be combined with the neo-antigen-based immunotherapy. INTACt will thus enable the creation of new business models for the highly pressured pharmaceutical industry.


year authors and title journal last update
List of publications.
2018 Michal Alon, Rand Arafeh, Joo Sang Lee, Sanna Madan, Shelly Kalaora, Adi Nagler, Tereza Abgarian, Polina Greenberg, Eytan Ruppin, Yardena Samuels
CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.25805
Oncotarget 9/58 2019-06-05
2018 Michal Alon, Rafi Emmanuel, Nouar Qutob, Anna Bakhman, Victoria Peshti, Alexandra Brodezki, David Bassan, Mickey Kosloff, Yardena Samuels
Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma
published pages: 641-648, ISSN: 1755-1471, DOI: 10.1111/pcmr.12705
Pigment Cell & Melanoma Research 31/5 2019-06-05

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INTACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Mass Politics of Disintegration

Read More  


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SUExp (2018)

Strategic Uncertainty: An Experimental Investigation

Read More